Tesa IPA Blend Peptide: What It Is and How It Works

Tesa IPA blend peptide is a research combination that pairs tesamorelin acetate with ipamorelin acetate in a single vial. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, and ipamorelin is a selective ghrelin receptor agonist, so the two compounds drive growth hormone release through different receptors. Neither the blend nor ipamorelin on its own is FDA-approved for general human use, and tesamorelin is approved only for a narrow clinical indication.

What's Inside a Tesa IPA Blend

A tesa IPA blend is normally sold as a lyophilized powder containing both peptides, often in roughly equal amounts. Common vial sizes run from 5 mg total to 10 mg total, with larger research quantities available from some suppliers. The ratio matters, because a 1:1 blend behaves very differently from a 4:1 blend when someone calculates units per injection.

Peptide	Class	Receptor target	FDA status in the US
Tesamorelin	GHRH analog	GHRH receptor	Approved as Egrifta for HIV-associated lipodystrophy
Ipamorelin	Ghrelin receptor agonist	GHS-R1a	Not approved for human use

Reputable suppliers ship a certificate of analysis that lists purity by HPLC and identity by mass spectrometry. A certificate of analysis is not a safety guarantee, but it is the minimum documentation worth checking before any laboratory work begins.

How Tesamorelin and Ipamorelin Work Together

Tesamorelin mimics the body's own GHRH signal, while ipamorelin mimics ghrelin at the GHS-R1a receptor. Because those are separate pathways, the pairing is usually described as complementary rather than redundant. Tesamorelin and ipamorelin act on different receptors, so a blend is not simply a double dose of one compound.

In animal and early human studies, ipamorelin was noted for selectivity, meaning it triggered growth hormone release with less impact on cortisol, prolactin, and appetite than older secretagogues. Tesamorelin's approved use targets visceral fat reduction in adults with HIV-associated lipodystrophy. Research interest in the blend comes from the idea that a GHRH signal plus a ghrelin signal may produce a larger pulse than either compound alone.

Tesa/IPA Blend Reconstitution: Step by Step

For tesa/ipa blend reconstitution, most suppliers recommend bacteriostatic water rather than plain sterile water, because the benzyl alcohol preservative extends usable shelf life. Add the diluent slowly and let the powder dissolve on its own.

1. Wipe the rubber stopper of the peptide vial and the diluent vial with an alcohol swab.
2. Draw the desired volume of bacteriostatic water into a syringe.
3. Inject the water slowly against the inside glass wall rather than directly onto the powder.
4. Swirl the vial gently until the powder is fully dissolved. Never shake it.
5. Label the vial with the date and the final concentration, then refrigerate it.

Total peptide in vial	Bacteriostatic water added	Approximate concentration
5 mg	2 mL	2.5 mg/mL
10 mg	2 mL	5 mg/mL
10 mg	5 mL	2 mg/mL
15 mg	3 mL	5 mg/mL

After mixing, store the vial between 2 and 8 degrees Celsius and keep it away from light. Do not freeze a reconstituted vial. A solution that stays cloudy or shows visible particles should be discarded.

Tesa IPA Peptide Dosage Reported in Research Protocols

Reported tesa ipa peptide dosage figures come from community logs and vendor guides, not from controlled trials of the blend itself. Published clinical dosing exists only for tesamorelin alone, at 2 mg subcutaneously once daily, and for ipamorelin only in small early-stage studies.

Peptide	Range reported in community guides	Typical frequency
Tesamorelin alone	1-2 mg	Once daily
Ipamorelin alone	100-300 mcg	2-3 times daily
1:1 tesa IPA blend	1-2 mg total	Once daily, evening

A typical tesa ipa blend protocol in online guides usually calls for a single evening injection timed to a fasting window. Those numbers are informal. Anyone considering human use should discuss dosing with a licensed healthcare professional rather than copying a forum post.

What Online Communities Report

Threads on tesa/ipa blend reddit and similar forums are the main place users compare notes, and every report there is anecdotal by definition. Common themes include water retention, tingling in the hands, increased hunger, injection site irritation, and cost. Many posters also admit that results are hard to separate from changes in training, diet, and sleep.

Community enthusiasm is not evidence of efficacy or safety. Anecdotes cannot show whether a benefit came from the peptide, the placebo effect, or unrelated lifestyle changes.

How Tesa IPA Compares With Other Peptide Blends

A tesa ipa cjc blend adds CJC-1295, a longer-acting GHRH analog, which changes the timing profile of the stack. Other common pairings include ipamorelin with CJC-1295 without DAC, and separate fat-loss compounds such as retatrutide. Each option targets different receptors, so "stronger" depends entirely on the outcome being measured.

Blend	Components	Main difference
Tesa IPA	Tesamorelin + ipamorelin	Two pathways in one vial
Tesa IPA CJC	Tesamorelin + ipamorelin + CJC-1295	Longer-acting GHRH signal
IPA + CJC (no DAC)	Ipamorelin + CJC-1295 without DAC	Classic pairing without tesamorelin
Retatrutide + tesamorelin	GLP-1/GIP/glucagon agonist + GHRH analog	Fat-loss focus, unrelated mechanism

Safety, Sourcing, and Legal Status in the US

Peptides sold for research are not FDA-approved for human use, and regulators do not verify their purity, sterility, or identity. Tesamorelin is a prescription product in the United States, which means legal human use requires a physician and a valid prescription. Ipamorelin has no approved human indication at all.

Reported concerns with growth hormone secretagogues include fluid retention, joint discomfort, elevated IGF-1, and effects on blood sugar. Regular blood work and medical supervision are the only reasonable way to monitor those risks. Anyone with a history of cancer, diabetes, or pituitary disease should treat these compounds as off-limits without a doctor's guidance.

RELATED PEPTIDE TOPICIpamorelin research

COMMON QUESTIONS

Frequently Asked Questions

What is a tesa IPA blend peptide?

A tesa IPA blend peptide is a single vial that contains both tesamorelin and ipamorelin, two compounds that stimulate growth hormone release through different receptors. It is sold as a research chemical rather than an approved medication. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, and ipamorelin is not FDA-approved for any human use.

How much bacteriostatic water do you add to a tesa IPA blend?

A common approach is to add 2 mL of bacteriostatic water to a 5 mg or 10 mg vial, which yields a concentration of 2.5 mg/mL or 5 mg/mL. Adding more diluent produces a weaker concentration and makes small volumes easier to measure. The water should be injected slowly against the vial wall, and the vial should be swirled rather than shaken.

Is a tesa IPA blend legal to buy in the United States?

Peptides marketed for laboratory research sit in a legal gray area, and the FDA has not approved a tesamorelin-ipamorelin combination for human use. Tesamorelin itself is a prescription drug, so using it without a prescription is not legal. Research-grade vials also are not tested for sterility the way pharmaceutical products are.